Інформація

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Ви шукаєте ""Pancreatic Neoplasms"" за критеріями: Temat


Tytuł:
Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients.
Autorzy:
Choi W; Center for Clinical Trials, National Cancer Center, Goyang, Korea.; Division of Cancer Biology, Cancer Molecular Biology Branch, Research Institute of National Cancer Center, Goyang, Korea.; Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea.
Kim YH; Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea.; Division of Technology Convergence, Cancer Molecular Imaging Branch, Research Institute of National Cancer Center, Goyang, Korea.
Woo SM; Division of Rare and Refractory Cancer, Immuno-oncology Branch, Research Institute of National Cancer Center, Goyang, Korea.; Center for Liver and Pancreatobiliary Cancer, Hospital, National Cancer Center, Goyang, Korea.
Yu Y; Division of Rare and Refractory Cancer, Targeted Therapy Branch of Research Institute, National Cancer Center, Goyang, Korea.
Lee MR; Division of Technology Convergence, Cancer Molecular Imaging Branch, Research Institute of National Cancer Center, Goyang, Korea.
Lee WJ; Center for Liver and Pancreatobiliary Cancer, Hospital, National Cancer Center, Goyang, Korea.; Division of Clinical Research, Cancer Outcome & Quality Improvement Branch, Research Institute of National Cancer Center, Goyang, Korea.
Chun JW; Center for Liver and Pancreatobiliary Cancer, Hospital, National Cancer Center, Goyang, Korea.; Division of Clinical Research, Interventional Medicine Branch, Research Institute of National Cancer Center, Goyang, Korea.
Sim SH; Center for Breast Cancer, National Cancer Center, Goyang, Korea.; Division of Rare and Refractory Cancer, Anticancer Resistance Branch, Research Institute of National Cancer Center, Goyang, Korea.
Chae H; Center for Breast Cancer, National Cancer Center, Goyang, Korea.; Center for Cancer Data Center, National Cancer Control Institute of National Cancer Center, Goyang, Korea.
Shim H; Department of Laboratory Medicine, National Cancer Center, Goyang, Korea.
Lee KS; Center for Clinical Trials, National Cancer Center, Goyang, Korea.; Center for Breast Cancer, National Cancer Center, Goyang, Korea.
Kong SY; Department of Cancer Biomedical Science, National Cancer Center Graduate School of Cancer Science and Policy, Goyang, Korea.; Division of Rare and Refractory Cancer, Targeted Therapy Branch of Research Institute, National Cancer Center, Goyang, Korea.; Department of Laboratory Medicine, National Cancer Center, Goyang, Korea.
Показати більше
Źródło:
Cancer research and treatment [Cancer Res Treat] 2023 Oct; Vol. 55 (4), pp. 1077-1086. Date of Electronic Publication: 2023 Jun 12.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/pathology
Breast Neoplasms*/drug therapy
Breast Neoplasms*/pathology
Peritoneal Neoplasms*/pathology
Humans ; Female ; Ascites ; Precision Medicine ; Organoids/pathology ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
Pancreatic Cancer: A Review of Current Treatment and Novel Therapies.
Autorzy:
Kolbeinsson HM; Spectrum Health General Surgery Residency, Grand Rapids, Michigan, USA.; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.
Chandana S; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.; Cancer and Hematology Centers of Western Michigan, PC, Grand Rapids, Michigan, USA.
Wright GP; Spectrum Health General Surgery Residency, Grand Rapids, Michigan, USA.; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.; Division of Surgical Oncology, Spectrum Health Medical Group, Grand Rapids, Michigan, USA.
Chung M; Spectrum Health General Surgery Residency, Grand Rapids, Michigan, USA.; Department of Surgery, Michigan State University College of Human Medicine, Grand Rapids, Michigan, USA.; Division of Surgical Oncology, Spectrum Health Medical Group, Grand Rapids, Michigan, USA.
Показати більше
Źródło:
Journal of investigative surgery : the official journal of the Academy of Surgical Research [J Invest Surg] 2023 Dec 31; Vol. 36 (1), pp. 2129884. Date of Electronic Publication: 2022 Oct 03.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Pancreatic Neoplasms*/therapy
Pancreatic Neoplasms*/drug therapy
Antineoplastic Agents*/therapeutic use
Humans ; United States ; Combined Modality Therapy ; Neoadjuvant Therapy ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
The suppressive efficacy of THZ1 depends on KRAS mutation subtype and is associated with super-enhancer activity and the PI3K/AKT/mTOR signalling in pancreatic ductal adenocarcinoma: A hypothesis-generating study.
Autorzy:
Huang L; Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yang H; Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Chen K; School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China.
Yuan J; Department of Pathology, Chinese PLA General Hospital, Beijing, China.
Li J; Department of Pathology, Chinese PLA General Hospital, Beijing, China.
Dai G; Department of Medical Oncology, Chinese PLA General Hospital, Beijing, China.
Gu M; School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou, China.; Academy of Chinese Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Shi Y; Department of General Surgery, Shanghai Seventh People's Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Показати більше
Źródło:
Clinical and translational medicine [Clin Transl Med] 2023 Dec; Vol. 13 (12), pp. e1500.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/genetics
Carcinoma, Pancreatic Ductal*/metabolism
Humans ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/metabolism ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins p21(ras)/genetics ; Proto-Oncogene Proteins p21(ras)/metabolism ; TOR Serine-Threonine Kinases/genetics ; TOR Serine-Threonine Kinases/metabolism ; Mutation/genetics ; Cyclin-Dependent Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
Timing of start of systemic treatment in patients with asymptomatic metastasized pancreatic cancer (TIMEPAN): a protocol of a multicenter prospective patient preference non-randomized trial.
Autorzy:
Augustinus S; Amsterdam UMC, Department of Surgery, University of Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Amsterdam, The Netherlands.
Broekman T; Cancer Center Amsterdam, Amsterdam, The Netherlands.; Amsterdam UMC, Department of Medical Oncology, University of Amsterdam, Amsterdam, The Netherlands.
Creemers GJ; Department of Medical Oncology, Catherina Hospital, Eindhoven, The Netherlands.
Daamen LA; Division of Imaging & Oncology, University Medical Center Utrecht Cancer Center, Utrecht University, Utrecht, The Netherlands.; Department of Surgery, University Medical Center Utrecht Cancer Center, St Antonius Hospital Nieuwegein, Regional Academic Cancer Center Utrecht, University of Utrecht, Utrecht, The Netherlands.
van Dieren S; Amsterdam UMC, Department of Surgery, University of Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Amsterdam, The Netherlands.
de Groot JB; Department of Medical Oncology, Oncology Center Isala, Zwolle, The Netherlands.
Cirkel GA; Department of Medical Oncology, Regional Academic Cancer Center Utrecht, Meander Medisch Centrum, Amersfoort, The Netherlands.
Homs MYV; Department of Medical Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.
van Laarhoven HWM; Cancer Center Amsterdam, Amsterdam, The Netherlands.; Amsterdam UMC, Department of Medical Oncology, University of Amsterdam, Amsterdam, The Netherlands.
van Leeuwen L; Department of Medical Oncology, Regional Academic Cancer Center Utrecht, Diakonessenhuis, Utrecht, The Netherlands.
Los M; Department of Medical Oncology, Regional Academic Cancer Center Utrecht, St. Antonius Ziekenhuis, Nieuwegein, The Netherlands.
Luelmo SAC; Department of Medical Oncology, Leids Universitair Medisch Centrum, Leiden, The Netherlands.
van Oijen MGH; Cancer Center Amsterdam, Amsterdam, The Netherlands.; Amsterdam UMC, Department of Medical Oncology, University of Amsterdam, Amsterdam, The Netherlands.
Spierings LEAM; Department of Medical Oncology, Alrijne Ziekenhuis, Leiderdorp, The Netherlands.
de Vos-Geelen J; Department of Medical Oncology, GROW, Maastricht UMC, Maastsricht, The Netherlands.
Besselink MG; Amsterdam UMC, Department of Surgery, University of Amsterdam, Amsterdam, The Netherlands.; Cancer Center Amsterdam, Amsterdam, The Netherlands.
Wilmink JW; Cancer Center Amsterdam, Amsterdam, The Netherlands.; Amsterdam UMC, Department of Medical Oncology, University of Amsterdam, Amsterdam, The Netherlands.
Показати більше
Corporate Authors:
Dutch Pancreatic Cancer Group
Źródło:
Acta oncologica (Stockholm, Sweden) [Acta Oncol] 2023 Dec; Vol. 62 (12), pp. 1973-1978. Date of Electronic Publication: 2023 Nov 25.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/pathology
Patient Preference*
Humans ; Multicenter Studies as Topic ; Pancreas/pathology ; Prospective Studies ; Clinical Trials as Topic ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity.
Autorzy:
Zheng Q; Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.; State Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Tang J; Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.; State Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Aicher A; Precision Immunotherapy, Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan.; Immunology Research and Development Center, China Medical University, Taichung, Taiwan.
Bou Kheir T; Barts Cancer Institute, Queen Mary University of London, London, UK.
Sabanovic B; Pancreatic Cancer Heterogeneity Lab, Candiolo Cancer Institute - FPO - IRCCS, Candiolo, Turin, Italy.
Ananthanarayanan P; Pancreatic Cancer Heterogeneity Lab, Candiolo Cancer Institute - FPO - IRCCS, Candiolo, Turin, Italy.
Reina C; Pancreatic Cancer Heterogeneity Lab, Candiolo Cancer Institute - FPO - IRCCS, Candiolo, Turin, Italy.
Chen M; Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.; State Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Gu JM; Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
He B; National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, China.
Alcala S; Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Instituto de Investigaciones Biomédicas 'Alberto Sols' CSIC-UAM, Chronic Diseases and Cancer Area 3 Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Centro de Investigación Biomédica en Red, Área Cáncer, CIBERONC, ISCIII, Madrid, Spain.
Behrens D; Experimental Pharmacology and Oncology Berlin-Buch GmbH, Berlin, Germany.
Lawlo RT; Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.; ARC-Net, Applied Research On Cancer Centre, University of Verona, Verona, Italy.
Scarpa A; Department of Diagnostics and Public Health, Section of Pathology, University of Verona, Verona, Italy.; ARC-Net, Applied Research On Cancer Centre, University of Verona, Verona, Italy.
Hidalgo M; Clinical Research Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.
Sainz B Jr; Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain.; Instituto de Investigaciones Biomédicas 'Alberto Sols' CSIC-UAM, Chronic Diseases and Cancer Area 3 Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Centro de Investigación Biomédica en Red, Área Cáncer, CIBERONC, ISCIII, Madrid, Spain.
Sancho P; IIS Aragon, Hospital Universitario Miguel Servet, 50009, Saragossa, Spain. .
Heeschen C; Center for Single-Cell Omics, School of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China. .; State Key Laboratory of Systems Medicine for Cancer, Shanghai Jiao Tong University School of Medicine, Shanghai, China. .; Pancreatic Cancer Heterogeneity Lab, Candiolo Cancer Institute - FPO - IRCCS, Candiolo, Turin, Italy. .; Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. .
Показати більше
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Nov 28; Vol. 42 (1), pp. 323. Date of Electronic Publication: 2023 Nov 28.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/genetics
Carcinoma, Pancreatic Ductal*/metabolism
Humans ; Animals ; Mice ; Signal Transduction ; Proto-Oncogene Proteins c-myc/genetics ; Proto-Oncogene Proteins c-myc/metabolism ; Cell Line, Tumor ; Neoplasm Recurrence, Local/pathology ; Neoplastic Stem Cells/metabolism ; Receptors, Cytoplasmic and Nuclear/metabolism ; SOXB1 Transcription Factors/genetics ; SOXB1 Transcription Factors/metabolism ; Pancreatic Neoplasms
SCR Disease Name:
Spinocerebellar Ataxia, Autosomal Recessive 2
Czasopismo naukowe
Tytuł:
Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer.
Autorzy:
Zheng S; Department of Pancreas Center, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, Guangdong, China.
Tian Q; School of medicine, South China University of Technology, Guangzhou, 510006, Guangdong Province, China.
Yuan Y; Guangdong cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China.
Sun S; Department of Pancreas Center, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, Guangdong, China.
Li T; School of medicine, South China University of Technology, Guangzhou, 510006, Guangdong Province, China.
Xia R; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China.
He R; Department of Pancreas Center, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, Guangdong, China.; Shantou University Medical College, Shantou, 515041, Guangdong province, China.
Luo Y; Department of Pancreas Center, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, Guangdong, China.
Lin Q; Department of Pancreas Center, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, Guangdong, China.
Fu Z; Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, Guangdong, China.; Department of Pancreatobiliary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, Guangdong, China.
Zhou Y; Department of Pancreas Center, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, Guangdong, China. .
Chen R; Department of Pancreas Center, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, Guangdong, China. .; School of medicine, South China University of Technology, Guangzhou, 510006, Guangdong Province, China. .; Guangdong cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, Guangdong, China. .
Hu C; Department of Pancreas Center, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, 510080, Guangdong, China. .
Показати більше
Źródło:
Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2023 Nov 28; Vol. 42 (1), pp. 324. Date of Electronic Publication: 2023 Nov 28.
Typ publikacji:
Journal Article
MeSH Terms:
Cancer-Associated Fibroblasts*/metabolism
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/genetics
Carcinoma, Pancreatic Ductal*/metabolism
Extracellular Vesicles*/metabolism
Humans ; Platinum/pharmacology ; Oxaliplatin/pharmacology ; Oxaliplatin/therapeutic use ; Sumoylation ; RNA/metabolism ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: A phase 2, multicenter, single arm, open label non-randomized study protocol.
Autorzy:
Karbhari A; Department of Radiology, Mayo Clinic, Rochester, Minnesota, United States of America.
Mosessian S; Clinical Development, Sofie Biosciences, Dulles, Virginia, United States of America.
Trivedi KH; Department of Radiology, Mayo Clinic, Rochester, Minnesota, United States of America.
Valla F Jr; Radiopharmaceutical and Contract Manufacturing, Sofie Biosciences, Dulles, Virginia, United States of America.
Jacobson M; Department of Radiology, Mayo Clinic, Rochester, Minnesota, United States of America.
Truty MJ; Department of Surgery, Mayo Clinic, Rochester, Minnesota, United States of America.
Patnam NG; Department of Radiology, Mayo Clinic, Rochester, Minnesota, United States of America.
Simeone DM; Departments of Surgery and Pathology, NYU Langone Health, New York, New York, United States of America.
Zan E; Department of Radiology, Weill Cornell Medicine, New York, New York, United States of America.
Brennan T; Discovery Life Sciences, Newtown, Pennsylvania, United States of America.
Chen H; Discovery Life Sciences, Newtown, Pennsylvania, United States of America.
Kuo PH; Departments of Medical Imaging, Medicine and Biomedical Engineering, University of Arizona, Tucson, Arizona, United States of America.
Herrmann K; Department of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Goenka AH; Department of Radiology, Mayo Clinic, Rochester, Minnesota, United States of America.
Показати більше
Źródło:
PloS one [PLoS One] 2023 Nov 27; Vol. 18 (11), pp. e0294564. Date of Electronic Publication: 2023 Nov 27 (Print Publication: 2023).
Typ publikacji:
Clinical Trial Protocol; Journal Article
MeSH Terms:
Pancreatic Neoplasms*/diagnostic imaging
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/pathology
Adenocarcinoma*/drug therapy
Carcinoma, Pancreatic Ductal*/diagnostic imaging
Carcinoma, Pancreatic Ductal*/drug therapy
Adult ; Humans ; Gallium Radioisotopes ; Positron-Emission Tomography ; Fibroblasts/pathology ; Positron Emission Tomography Computed Tomography ; Fluorodeoxyglucose F18/therapeutic use ; Multicenter Studies as Topic ; Clinical Trials, Phase II as Topic ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
Undifferentiated carcinoma of the pancreas with osteoclast-like giant cells: a case report.
Autorzy:
Chan W; Irvine Department of Radiological Sciences, University of California, 101 The City Drive South, Orange, CA, 92868, USA.
Park S; Irvine Department of Radiological Sciences, University of California, 101 The City Drive South, Orange, CA, 92868, USA.
Shirkhoda L; Irvine Department of Radiological Sciences, University of California, 101 The City Drive South, Orange, CA, 92868, USA.
O'Connell R; Irvine Department of Pathology and Laboratory Medicine, School of Medicine, University of California, University of California Irvine, Irvine, CA, 92697, USA.
Houshyar R; Irvine Department of Radiological Sciences, University of California, 101 The City Drive South, Orange, CA, 92868, USA. .
Показати більше
Źródło:
Journal of medical case reports [J Med Case Rep] 2023 Nov 16; Vol. 17 (1), pp. 477. Date of Electronic Publication: 2023 Nov 16.
Typ publikacji:
Case Reports; Journal Article
MeSH Terms:
Carcinoma*/surgery
Pancreatic Neoplasms*/diagnostic imaging
Pancreatic Neoplasms*/therapy
Pancreatic Neoplasms*/pathology
Adenocarcinoma*/diagnostic imaging
Adenocarcinoma*/therapy
Adenocarcinoma*/pathology
Humans ; Male ; Middle Aged ; Osteoclasts/pathology ; Pancreas/pathology ; Giant Cells/pathology ; Disease Progression ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy.
Autorzy:
Du X; Key Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China.; State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, Beijing, 100850, China.; Nanhu Laboratory, Jiaxing, 314002, China.
Yi X; State Key Laboratory of Proteomics, Institute of Basic Medical Sciences, National Center of Biomedical Analysis, Beijing, 100850, China.; Nanhu Laboratory, Jiaxing, 314002, China.
Zou X; Key Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China.; State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, Beijing, 100850, China.
Chen Y; State Key Laboratory of Proteomics, Institute of Basic Medical Sciences, National Center of Biomedical Analysis, Beijing, 100850, China.; Nanhu Laboratory, Jiaxing, 314002, China.
Tai Y; Department of Pathology, No.307 Hospital of PLA, Beijing, 100071, China.
Ren X; Key Laboratory of Structure-Based Drug Design and Discovery, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenhe District, Shenyang, 110016, China. .
He X; State Key Laboratory of Toxicology and Medical Countermeasures, Institute of Pharmacology and Toxicology, Beijing, 100850, China. .; Nanhu Laboratory, Jiaxing, 314002, China. .
Показати більше
Źródło:
BMC cancer [BMC Cancer] 2023 Nov 13; Vol. 23 (1), pp. 1102. Date of Electronic Publication: 2023 Nov 13.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma*
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Humans ; Prognosis ; Flutamide ; RNA ; Biomarkers ; Gene Expression Regulation, Neoplastic ; Protocadherins ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
An integrated study to decipher immunosuppressive cellular communication in the PDAC environment.
Autorzy:
Avşar G; Department of Bioengineering, Gebze Technical University, Kocaeli, Turkey. .; Turkish Academy of Sciences, Ankara, Turkey. .
Pir P; Department of Bioengineering, Gebze Technical University, Kocaeli, Turkey.
Показати більше
Źródło:
NPJ systems biology and applications [NPJ Syst Biol Appl] 2023 Nov 10; Vol. 9 (1), pp. 56. Date of Electronic Publication: 2023 Nov 10.
Typ publikacji:
Journal Article
MeSH Terms:
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Pancreatic Neoplasms*/pathology
Carcinoma, Pancreatic Ductal*/genetics
Carcinoma, Pancreatic Ductal*/metabolism
Carcinoma, Pancreatic Ductal*/pathology
Humans ; Communication ; Tumor Microenvironment/genetics ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
DCLRE1B promotes tumor progression and predicts immunotherapy response through METTL3-mediated m6A modification in pancreatic cancer.
Autorzy:
Li L; Faculty of Hepato-Pancreato-Biliary Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing, China.; Department of Surgery, Second Mobile Corps Hospital of Chinese People's Armed Police Force, Wuxi, China.
Wang F; Faculty of Hepato-Pancreato-Biliary Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Deng Z; Faculty of Hepato-Pancreato-Biliary Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Zhang G; Faculty of Hepato-Pancreato-Biliary Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Zhu L; Faculty of Hepato-Pancreato-Biliary Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing, China.
Zhao Z; Faculty of Hepato-Pancreato-Biliary Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing, China. .
Liu R; Faculty of Hepato-Pancreato-Biliary Surgery, the First Medical Center, Chinese PLA General Hospital, Beijing, China. .
Показати більше
Źródło:
BMC cancer [BMC Cancer] 2023 Nov 07; Vol. 23 (1), pp. 1073. Date of Electronic Publication: 2023 Nov 07.
Typ publikacji:
Journal Article
MeSH Terms:
Neoplastic Processes*
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/therapy
Humans ; Cell Transformation, Neoplastic ; Carcinogenesis ; Methyltransferases/genetics ; Exodeoxyribonucleases ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
Incidence and risk of pancreatic cancer in patients with acute or chronic pancreatitis: a population-based cohort study.
Autorzy:
Park SM; Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.; Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.
Kim KB; Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.; Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.
Han JH; Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.; Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.
Kim N; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.; Department of Internal Medicine, Seoul National University Bundang Hospital, Seungnam, Republic of Korea.
Kang TU; Health and Wellness College, Sungshin Women's University, Seoul, Republic of Korea.
Swan H; Department of Preventive Medicine, Korea University College of Medicine, 126-1, 5-ga, Inchon-ro, Seoul, 136-705, Republic of Korea.
Kim HJ; Department of Preventive Medicine, Korea University College of Medicine, 126-1, 5-ga, Inchon-ro, Seoul, 136-705, Republic of Korea. .; Department of Public Health, Graduate School, Korea University, Seoul, Republic of Korea. .
Показати більше
Źródło:
Scientific reports [Sci Rep] 2023 Nov 02; Vol. 13 (1), pp. 18930. Date of Electronic Publication: 2023 Nov 02.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Pancreatitis, Chronic*/complications
Pancreatitis, Chronic*/epidemiology
Pancreatic Neoplasms*/epidemiology
Pancreatic Neoplasms*/complications
Male ; Female ; Humans ; Incidence ; Cohort Studies ; Acute Disease ; Risk Factors ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
SDC1 and ITGA2 as novel prognostic biomarkers for PDAC related to IPMN.
Autorzy:
Zhang CL; Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Shen Q; Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Liu FD; Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Yang F; Beijing University of Chinese Medicine, Beijing, 100029, China.
Gao MQ; Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, 100102, China.
Jiang XC; Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Li Y; Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China.
Zhang XY; Beijing University of Chinese Medicine, Beijing, 100029, China.
En GE; Beijing University of Chinese Medicine, Beijing, 100029, China.
Pan X; Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China. .; Third Affiliated Hospital, Beijing University of Chinese Medicine, Beijing, 100029, China. .
Pang B; International Medical Department of Guang'anmen Hospital China Academy of Chinese Medical Sciences, Beijing, 100053, China. .
Показати більше
Źródło:
Scientific reports [Sci Rep] 2023 Oct 31; Vol. 13 (1), pp. 18727. Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Pancreatic Ductal*/diagnosis
Carcinoma, Pancreatic Ductal*/genetics
Carcinoma, Pancreatic Ductal*/metabolism
Pancreatic Intraductal Neoplasms*
Pancreatic Neoplasms*/diagnosis
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Humans ; Biomarkers, Tumor/genetics ; Prognosis ; Syndecan-1/genetics ; Tumor Microenvironment ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines.
Autorzy:
Witz A; Département de Biopathologie, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France. .; Université de Lorraine, CNRS UMR 7039 CRAN, Vandœuvre-lès-Nancy, France. .
Dardare J; Département de Biopathologie, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.; Université de Lorraine, CNRS UMR 7039 CRAN, Vandœuvre-lès-Nancy, France.
Francois A; Université de Lorraine, CNRS UMR 7039 CRAN, Vandœuvre-lès-Nancy, France.; Département Recherche, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.
Husson M; Département de Biopathologie, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.
Rouyer M; Département de Biopathologie, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.
Demange J; Département de Biopathologie, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.
Merlin JL; Département de Biopathologie, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.; Université de Lorraine, CNRS UMR 7039 CRAN, Vandœuvre-lès-Nancy, France.
Gilson P; Département de Biopathologie, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.; Université de Lorraine, CNRS UMR 7039 CRAN, Vandœuvre-lès-Nancy, France.
Harlé A; Département de Biopathologie, Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy, France.; Université de Lorraine, CNRS UMR 7039 CRAN, Vandœuvre-lès-Nancy, France.
Показати більше
Źródło:
Scientific reports [Sci Rep] 2023 Oct 31; Vol. 13 (1), pp. 18741. Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Journal Article
MeSH Terms:
Adenocarcinoma*/genetics
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/pathology
Humans ; BRCA1 Protein/genetics ; BRCA2 Protein/genetics ; CRISPR-Cas Systems ; Phthalazines/pharmacology ; Germ-Line Mutation ; Mutation ; MCF-7 Cells ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer.
Autorzy:
Tummala T; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.; Legorreta Cancer Center at Brown University, Providence, RI 02912, USA.
Sevilla Uruchurtu AS; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.; Legorreta Cancer Center at Brown University, Providence, RI 02912, USA.
Cruz A; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.; Legorreta Cancer Center at Brown University, Providence, RI 02912, USA.
Huntington KE; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.; Legorreta Cancer Center at Brown University, Providence, RI 02912, USA.
George A; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.; Legorreta Cancer Center at Brown University, Providence, RI 02912, USA.
Liguori NR; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.
Zhang L; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.; Legorreta Cancer Center at Brown University, Providence, RI 02912, USA.; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.
Zhou L; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.; Legorreta Cancer Center at Brown University, Providence, RI 02912, USA.; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.; Joint Program in Cancer Biology, Lifespan Health System and Brown University, Providence, RI 02903, USA.
Abbas AE; Legorreta Cancer Center at Brown University, Providence, RI 02912, USA.; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.; Joint Program in Cancer Biology, Lifespan Health System and Brown University, Providence, RI 02903, USA.; Department of Surgery, Brown University, Providence, RI 02912, USA.
Azzoli CG; Legorreta Cancer Center at Brown University, Providence, RI 02912, USA.; Joint Program in Cancer Biology, Lifespan Health System and Brown University, Providence, RI 02903, USA.; Hematology/Oncology Division, Department of Medicine, Lifespan Health System and Brown University, Providence, RI 02903, USA.
El-Deiry WS; Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.; Legorreta Cancer Center at Brown University, Providence, RI 02912, USA.; Department of Pathology and Laboratory Medicine, Warren Alpert Medical School, Brown University, Providence, RI 02903, USA.; Joint Program in Cancer Biology, Lifespan Health System and Brown University, Providence, RI 02903, USA.; Hematology/Oncology Division, Department of Medicine, Lifespan Health System and Brown University, Providence, RI 02903, USA.
Показати більше
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Oct 31; Vol. 30 (11), pp. 9611-9626. Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Journal Article
MeSH Terms:
Fluorouracil*/pharmacology
Fluorouracil*/therapeutic use
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/pathology
Humans ; Irinotecan/pharmacology ; Irinotecan/therapeutic use ; Carbolines/pharmacology ; Carbolines/therapeutic use ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists.
Autorzy:
Garajová I; Medical Oncology Unit, University Hospital of Parma, 43125 Parma, Italy.
Peroni M; Medical Oncology Unit, University Hospital of Parma, 43125 Parma, Italy.
Gelsomino F; Department of Oncology and Hematology, University Hospital of Modena, 41124 Modena, Italy.
Leonardi F; Medical Oncology Unit, University Hospital of Parma, 43125 Parma, Italy.
Показати більше
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2023 Oct 31; Vol. 30 (11), pp. 9587-9601. Date of Electronic Publication: 2023 Oct 31.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/pathology
Carcinoma, Pancreatic Ductal*/drug therapy
Oncologists*
Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Deoxycytidine/therapeutic use ; Paclitaxel/therapeutic use ; Pancreas/pathology ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
Lactobacillus casei combined with Lactobacillus reuteri alleviate pancreatic cancer by inhibiting TLR4 to promote macrophage M1 polarization and regulate gut microbial homeostasis.
Autorzy:
Zhu Z; Department of Hepatobiliary and Pancreatic Surgery, Zhuzhou Central Hospital, Zhuzhou, China.
Yi B; Department of Hepatobiliary and Pancreatic Surgery, Zhuzhou Central Hospital, Zhuzhou, China.
Tang Z; Department of Hepatobiliary and Pancreatic Surgery, Zhuzhou Central Hospital, Zhuzhou, China.
Chen X; Department of Hepatobiliary and Pancreatic Surgery, Zhuzhou Central Hospital, Zhuzhou, China.; Department of Trauma Center, Zhuzhou Central Hospital, Zhuzhou, China.
Li M; Department of Trauma Center, Zhuzhou Central Hospital, Zhuzhou, China.
Xu T; Department of Hepatobiliary and Pancreatic Surgery, Zhuzhou Central Hospital, Zhuzhou, China.
Zhao Z; Department of Hepatobiliary and Pancreatic Surgery, Zhuzhou Central Hospital, Zhuzhou, China. .
Tang C; Department of Hepatobiliary and Pancreatic Surgery, Zhuzhou Central Hospital, Zhuzhou, China. .; Department of Trauma Center, Zhuzhou Central Hospital, Zhuzhou, China. .
Показати більше
Źródło:
BMC cancer [BMC Cancer] 2023 Oct 30; Vol. 23 (1), pp. 1044. Date of Electronic Publication: 2023 Oct 30.
Typ publikacji:
Journal Article
MeSH Terms:
Limosilactobacillus reuteri*
Lacticaseibacillus casei*
Gastrointestinal Microbiome*
Pancreatic Neoplasms*/therapy
Pancreatic Neoplasms*/metabolism
Mice ; Humans ; Animals ; Toll-Like Receptor 4/metabolism ; Mice, Nude ; Chromatography, Liquid ; Oxypurinol/metabolism ; Oxypurinol/pharmacology ; Tandem Mass Spectrometry ; Macrophages/metabolism ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
KDM5 family of demethylases promotes CD44-mediated chemoresistance in pancreatic adenocarcinomas.
Autorzy:
Wang D; Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China.; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
Zhang Y; Hunan Engineering and Technology Research Center for Agricultural Big Data Analysis and Decision-Making, Hunan Agricultural University, Changsha, China.
Liao Z; Department of Nephrology, Xiangya Hospital, Central South University, Changsha, China.; Division of Translational Immunology, III, Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ge H; Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China.; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.; Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Güngör C; Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Li Y; Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China. .; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China. .; NHC Key Laboratory of Cancer Proteomics and Laboratory of Structural Biology, Xiangya Hospital, Central South University, Changsha, China. .
Показати більше
Źródło:
Scientific reports [Sci Rep] 2023 Oct 25; Vol. 13 (1), pp. 18250. Date of Electronic Publication: 2023 Oct 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Adenocarcinoma*/drug therapy
Adenocarcinoma*/genetics
Carcinoma, Pancreatic Ductal*/drug therapy
Carcinoma, Pancreatic Ductal*/genetics
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/pathology
Humans ; Cell Line, Tumor ; Drug Resistance, Neoplasm/genetics ; Hyaluronan Receptors/genetics ; Phosphatidylinositol 3-Kinases ; Retinoblastoma-Binding Protein 2 ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
Lymph node metastasis related gene BICC1 promotes tumor progression by promoting EMT and immune infiltration in pancreatic cancer.
Autorzy:
Meng F; Minimally invasive Center of Hepatobiliary and Pancreatic surgery, The Second Hospital of Harbin, Harbin, Heilongjiang, China.
Hua S; Hepatobiliary and Pancreatic Surgery, The Second Hospital of Harbin, Harbin, Heilongjiang, China.
Chen X; Hepatobiliary and Pancreatic Surgery, The Second Hospital of Harbin, Harbin, Heilongjiang, China.
Meng N; Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Lan T; Department of Rehabilitation, The Second Hospital of Harbin, Ward A, Harbin, Heilongjiang, China. .
Показати більше
Źródło:
BMC medical genomics [BMC Med Genomics] 2023 Oct 25; Vol. 16 (1), pp. 263. Date of Electronic Publication: 2023 Oct 25.
Typ publikacji:
Journal Article
MeSH Terms:
Epithelial-Mesenchymal Transition*/genetics
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/pathology
RNA-Binding Proteins*/genetics
Humans ; Lymphatic Metastasis ; Prognosis ; Pancreatic Neoplasms
Czasopismo naukowe
Tytuł:
SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer.
Autorzy:
Kim MJ; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul 03722, Republic of Korea.
Kim HS; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.
Kang HW; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul 03722, Republic of Korea.
Lee DE; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.
Hong WC; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.; Yonsei University College of Medicine, Seoul 06229, Republic of Korea.
Kim JH; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.; Yonsei University College of Medicine, Seoul 06229, Republic of Korea.
Kim M; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.; Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul 03722, Republic of Korea.
Cheong JH; Brain Korea 21 PLUS Project for Medical Science, Yonsei University, Seoul 03722, Republic of Korea.; Department of Surgery, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.
Kim HJ; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.
Park JS; Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06229, Republic of Korea.
Показати більше
Źródło:
Cells [Cells] 2023 Oct 23; Vol. 12 (20). Date of Electronic Publication: 2023 Oct 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Ferroptosis*
Pancreatic Neoplasms*/drug therapy
Pancreatic Neoplasms*/genetics
Pancreatic Neoplasms*/metabolism
Amino Acid Transport Systems, Neutral*
Animals ; Mice ; Humans ; Gemcitabine ; Deoxycytidine/pharmacology ; Deoxycytidine/therapeutic use ; Glutamine ; Drug Resistance, Neoplasm ; Cell Line, Tumor ; Pancreatic Neoplasms
Czasopismo naukowe